Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Cell and Molecular Biology of Ovarian Cancer : Updates, Insights and New Frontiers
| Cell and Molecular Biology of Ovarian Cancer : Updates, Insights and New Frontiers |
| Autore | Schatten Heide |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing AG, , 2024 |
| Descrizione fisica | 1 online resource (133 pages) |
| Collana | Advances in Experimental Medicine and Biology Series |
| Soggetto topico | Ovarian Neoplasms |
| ISBN |
9783031583117
9783031583100 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Contents -- 1: Microtubule-Targeting Agents: Disruption of the Cellular Cytoskeleton as a Backbone of Ovarian Cancer Therapy -- 1.1 Microtubules -- 1.1.1 Formation and Features -- 1.1.2 Role in Cellular Function -- 1.2 NCCN-Approved Agents for Use in Ovarian Cancer -- 1.3 Microtubule-Stabilizing Agents -- 1.3.1 Paclitaxel -- 1.3.2 Nab-paclitaxel -- 1.3.3 Docetaxel -- 1.3.4 Ixabepilone -- 1.4 Microtubule-Destabilizing Agents -- 1.4.1 Vincristine -- 1.4.1.1 Vinblastine -- 1.4.2 Vinorelbine -- 1.5 Mechanisms of Resistance -- References -- 2: Tubulin Complexity in Cancer and Metastasis -- 2.1 Tubulin Complexity -- 2.2 Microtubule-Associated Proteins (MAPs) -- 2.3 Tubulin Posttranslational Modifications (PTMs) -- 2.4 Microtentacles -- References -- 3: The Impact of Centrosome Pathologies on Ovarian Cancer Development and Progression with a Focus on Centrosomes as Therapeutic Target -- 3.1 Introduction -- 3.2 Structure, Composition, and Function of Centrosomes and Abnormalities/Dysregulation in Ovarian Cancer -- 3.3 Centrosome Regulation in Normal Cell Cycles -- 3.4 Centrosome Dysregulation, Abnormalities in Ovarian Cancer, and New Research to Correct Centrosome Abnormalities -- 3.4.1 Centrosome Clustering -- 3.5 The Role of Primary Cilia in Ovarian Cancer -- 3.6 Centrosomes as Target for Ovarian Cancer Therapy -- 3.7 Conclusion and Future Directions -- References -- 4: Drug-Resistant Epithelial Ovarian Cancer: Current and Future Perspectives -- 4.1 Introduction to Epithelial Ovarian Cancer and Its Subtypes -- 4.1.1 Type I Neoplasms -- 4.1.1.1 Low-Grade Serous Ovarian Cancer (LGSOC) Subtype -- 4.1.1.2 Sero-mucinous Subtype -- 4.1.1.3 Mucinous Ovarian Carcinomas (MOC) -- 4.1.1.4 Endometrioid Ovarian Carcinomas (EEOC) -- 4.1.1.5 Clear Cell Ovarian Carcinomas (CCOC) -- 4.1.1.6 Brenner Tumours.
4.1.2 Type II Neoplasms -- 4.1.2.1 High-Grade Serous Ovarian Cancer (HGSOC) -- 4.1.2.2 High Grade EEOC -- 4.1.2.3 Undifferentiated Carcinoma -- 4.2 Current Diagnostic Strategies -- 4.3 Current Treatment Modalities -- 4.3.1 Targeted Therapy -- 4.4 Resistance, a Major Limitation Against Currently Available Therapeutics -- 4.5 Elucidating Drug Resistance Mechanisms: Understanding the Molecular Players -- 4.5.1 Decreased Intracellular Drug Accumulation and Increased Drug Export -- 4.5.1.1 Influx Transporters -- 4.5.1.2 Efflux Transporters -- 4.5.2 Increased Drug Inactivation -- 4.5.2.1 CYP System -- 4.5.2.2 Glutathione S-Transferase (GST) -- 4.5.2.3 Uridine Diphospho-glucuronosyltransferase (UGT) Superfamily -- 4.5.3 Resistance to PARP Inhibitors and HR Pathways -- 4.5.4 Deregulated Autophagy -- 4.5.5 Altered Metabolism -- 4.5.5.1 Glucose Metabolism -- 4.5.5.2 Fatty Acid Metabolism -- 4.5.5.3 Altered Glutamine Metabolism -- 4.5.6 Evasion of Apoptosis -- 4.5.7 Cancer Stem Cells -- 4.5.8 Role of miRNAs and lncRNA -- 4.6 An Insight Into the Upcoming Therapies and Clinical Trials -- 4.6.1 Overcoming Bevacizumab Resistance Through Peptide Fusion Protein Trebananib -- 4.6.2 Emerging Targeted Therapies -- 4.6.2.1 Anti-angiogenic agents -- 4.6.2.2 Targeting the DNA Repair Pathway -- 4.6.2.3 Receptor Tyrosine Kinase Inhibitors -- 4.6.2.4 Epidermal Growth Factor Receptor- Family Targeted Inhibitors -- 4.6.2.5 MEK Inhibitors -- 4.6.2.6 PI3K Inhibitors -- 4.6.3 Strategies to Develop Additional Synthetic Lethal Therapies -- 4.6.3.1 Wee1 Inhibition -- 4.6.3.2 CHK1 Inhibitors -- 4.6.4 Sequential and Combinatorial Approaches Using Chemotherapeutics and Molecular Targeted Agents -- 4.6.5 Targeting Immune Evasion Mechanisms -- 4.6.5.1 Adoptive T-Cell Therapies -- 4.6.6 Targeting the Tumour Microenvironment. 4.6.7 Vaccine-Based Therapies -- 4.6.7.1 Cell-Based Vaccine-Cvac -- 4.6.7.2 p53 Vaccine-p53MVA -- 4.6.7.3 Tumour-Associated Antigens-DPX-Survivac -- 4.7 Conclusion -- References -- 5: The Role of the Human Microbiome in Epithelial Ovarian Cancer -- 5.1 Introduction -- 5.2 Human Microbiome -- 5.3 Epithelial Ovarian Cancer and the Human Microbiome -- 5.3.1 Lower Reproductive Tract -- 5.3.2 Upper Reproductive Tract -- 5.3.3 Gastrointestinal Tract -- 5.4 Conclusions and Future Directions -- References -- 6: Insights into the Microbial Composition of Intratumoral, Reproductive Tract, and Gut Microbiota in Ovarian Cancer Patients -- 6.1 Introduction -- 6.2 Overview of Ovarian Cancer Associated Microbiota -- 6.2.1 Ovarian Cancer Tissue Microbial Composition and Origin -- 6.2.2 Reproductive Tract Microbial Composition -- 6.2.3 The Relationship Between Reproductive Tract Microbiota and Ovarian Cancer -- 6.2.4 Gut Microbiota in Ovarian Cancer Patients and Animal Models -- 6.3 Functions of Ovarian Cancer-Associated Microbiota Metabolites -- 6.3.1 Microbial Metabolites Affect Ovarian Cancer Development -- 6.3.2 Microbiota Affect Hormone Regulation and Carcinogenesis -- 6.3.3 Microbiota Regulate Inflammatory and Immune Regulation -- 6.4 Bacteria in Therapeutics and Diagnostics of Ovarian Cancer -- 6.4.1 The Role of Microbiota in Therapeutic Effects in Ovarian Cancer -- 6.4.1.1 The Potential Role of Microbiota in Ovarian Cancer Therapy Drug Resistance -- 6.4.1.2 A Dual Role of Antibiotic Therapy for Ovarian Cancer -- 6.4.2 Nutrient and Diet Modify Microbiome and Help Prevent Ovarian Cancer -- 6.5 Conclusion and Future Perspectives -- References -- 7: The Impact of Mitochondria in Ovarian Cancer Cell Metabolism, Proliferation, and Metastasis -- 7.1 Introduction -- 7.1.1 Mitochondrial Vulnerabilities Underlying Dysfunction and Disease. 7.1.2 Mitochondrial Dysfunction in Ovarian Cancer -- 7.1.3 Present Treatment Difficulties for Ovarian Cancer and New Potential Treatment Strategies to Target Ovarian Cancer Mitochondrial Metabolism -- 7.1.4 Biobehavioral Factors Influencing Ovarian Cancer Development -- 7.2 Conclusions and Future Perspectives -- References -- Index. |
| Record Nr. | UNINA-9910865232203321 |
Schatten Heide
|
||
| Cham : , : Springer International Publishing AG, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clinical ovarian & other gynecologic cancer
| Clinical ovarian & other gynecologic cancer |
| Pubbl/distr/stampa | [New York], : Elsevier Inc., ©2012- |
| Descrizione fisica | 1 online resource |
| Disciplina | 616.99/465 |
| Soggetto topico |
Generative organs, Female - Cancer
Ovaries - Cancer Ovarian Neoplasms Genital Neoplasms, Female |
| Soggetto genere / forma |
Periodical
Periodicals. |
| Soggetto non controllato | Oncology |
| ISSN | 2212-9561 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Clinical ovarian and other gynecologic cancer |
| Record Nr. | UNINA-9910141441003321 |
| [New York], : Elsevier Inc., ©2012- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clinical ovarian & other gynecologic cancer
| Clinical ovarian & other gynecologic cancer |
| Pubbl/distr/stampa | [New York], : Elsevier Inc., ©2012- |
| Descrizione fisica | 1 online resource |
| Disciplina | 616.99/465 |
| Soggetto topico |
Generative organs, Female - Cancer
Ovaries - Cancer Ovarian Neoplasms Genital Neoplasms, Female |
| Soggetto genere / forma |
Periodical
Periodicals. |
| Soggetto non controllato | Oncology |
| ISSN | 2212-9561 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Clinical ovarian and other gynecologic cancer |
| Record Nr. | UNISA-996207549103316 |
| [New York], : Elsevier Inc., ©2012- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Clinical ovarian cancer and other gynecologic malignancies
| Clinical ovarian cancer and other gynecologic malignancies |
| Pubbl/distr/stampa | Dallas, TX, : CIG Media Group, ©2008-©2011 |
| Disciplina | 614 |
| Soggetto topico |
Ovaries - Cancer
Generative organs, Female - Cancer Ovarian Neoplasms Genital Neoplasms, Female |
| Soggetto genere / forma |
Periodical
Periodicals. |
| Soggetto non controllato | Oncology |
| ISSN | 1941-4404 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Clinical ovarian cancer |
| Record Nr. | UNINA-9910144994103321 |
| Dallas, TX, : CIG Media Group, ©2008-©2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Clinical ovarian cancer and other gynecologic malignancies
| Clinical ovarian cancer and other gynecologic malignancies |
| Pubbl/distr/stampa | Dallas, TX, : CIG Media Group, ©2008-©2011 |
| Disciplina | 614 |
| Soggetto topico |
Ovaries - Cancer
Generative organs, Female - Cancer Ovarian Neoplasms Genital Neoplasms, Female |
| Soggetto genere / forma |
Periodical
Periodicals. |
| Soggetto non controllato | Oncology |
| ISSN | 1941-4404 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Clinical ovarian cancer |
| Record Nr. | UNISA-996204253903316 |
| Dallas, TX, : CIG Media Group, ©2008-©2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Management of adnexal mass
| Management of adnexal mass |
| Pubbl/distr/stampa | [Place of publication not identified], : AHRQ, 2006 |
| Descrizione fisica | 1 online resource |
| Disciplina | 618.1/1 |
| Collana |
Evidence Reports/Technology Assessments
AHRQ publication |
| Soggetto topico |
Endocrine Gland Neoplasms
Ovarian Diseases Cysts Evidence-Based Practice Clinical Medicine Genital Neoplasms, Female Medicine Adnexal Diseases Neoplasms Gonadal Disorders Endocrine System Diseases Health Occupations Neoplasms by Site Urogenital Neoplasms Female Urogenital Diseases Diseases Genital Diseases, Female Female Urogenital Diseases and Pregnancy Complications Evidence-Based Medicine Ovarian Neoplasms Ovarian Cysts Health & Biological Sciences Gynecology & Obstetrics |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910698292303321 |
| [Place of publication not identified], : AHRQ, 2006 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Molecular diagnosis and targeting for gynecologic malignancy / / Seiji Isonishi, Yoshihiro Kikuchi, editors
| Molecular diagnosis and targeting for gynecologic malignancy / / Seiji Isonishi, Yoshihiro Kikuchi, editors |
| Edizione | [1st ed. 2021.] |
| Pubbl/distr/stampa | Gateway East, Singapore : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (VIII, 165 pages, 26 illustrations., 24 illustrations in color) |
| Disciplina | 616.99465 |
| Collana | Current Human Cell Research and Applications |
| Soggetto topico |
Generative organs, Female - Cancer
Genital Neoplasms, Female Ovarian Neoplasms Uterine Cervical Neoplasms Càncer Malalties de l'aparell genital femení Càncer d'ovari Càncer d'úter |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-336-013-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1 Cancer Stem Cells in gynecologic cancer -- 2 Patient-derived xenograft models in gynaecological malignancies -- 3 Cancer genomic profiling of gynecological malignancies by Todai OncoPanel, a twin DNA and RNA panel -- 4 Investigating the molecular carcinogenesis of ovarian high-grade serous cancer -- 5 The role of G protein-coupled receptor signaling in gynecologic malignancy -- 6 Tailor-made therapy according genetic alteration in epithelial ovarian cancers -- 7 Signaling and drug resistance -- 8 Molecular analysis in endometrial carcinoma -- 9 Molecular Landscape in Ovarian Clear Cell Carcinoma -- 10 Molecular pathology and clinicopathological significance of endometrial carcinoma -- 11 Novel approach for therapeutics of cervical cancer based on HPV-associated carcinogenesis at the cervix -- 12 Hereditary gynecological malignancy and molecular features. |
| Record Nr. | UNINA-9910483588903321 |
| Gateway East, Singapore : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
